Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631641 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
A Phase 2 study, sponsored by John Hays.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03631641 is a Phase 2 study that was terminated before completion, run by John Hays. The registered enrollment target is 3 participants.
The verdict
NCT03631641, a Phase 2 study, was terminated before completion, sponsored by John Hays.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab works in preventing colon adenomas in participants with Lynch syndrome and a history of surgery to remove part of the colon. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03631641
The ClinicalTrials.gov registry entry for NCT03631641 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Hays, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT03631641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03631641 about?
NCT03631641 is a clinical study titled "Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy". This phase II trial studies how well nivolumab works in preventing colon adenomas in participants with Lynch syndrome and a history of surgery to remove part of the colon. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT03631641?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-10-04. Estimated completion is 2021-01-25.
What interventions are being tested in trial NCT03631641?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03631641?
This trial is sponsored by John Hays, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.